PM
62
2
D
63
2
DVA
80
4
A
44
3
FE
57
2
EBAY
50
-2
URI
53
3
M
12
6
NWS
37
2
DUK
69
5
PPG
64
4
ILMN
38
2
VRSN
54
2
MS
55
7
ROST
63
2
IP
42
3
ED
58
2
WFC
52
2
UNH
59
2
VFC
56
11
PM
62
2
D
63
2
DVA
80
4
A
44
3
FE
57
2
EBAY
50
-2
URI
53
3
M
12
6
NWS
37
2
DUK
69
5
PPG
64
4
ILMN
38
2
VRSN
54
2
MS
55
7
ROST
63
2
IP
42
3
ED
58
2
WFC
52
2
UNH
59
2
VFC
56
11
Financhill
Back

Reshape Lifesciences 10K Form

Sell
34

RSLS
Reshape Lifesciences

Last Price:
0.16
Seasonality Move:
-15.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RSLS News And Ratings

See the #1 stock for the next 7 days that we like better than RSLS

RSLS Financial Statistics

Sales & Book Value

Annual Sales: $8.68M
Cash Flow: $-1.36M
Price / Cash Flow: 0
Annual Sales: $0.10
Price / Book: 1.62

Profitability

EPS (TTM): -1.24240
Net Income (TTM): $-9.02M
Gross Margin: $5.55M
Return on Equity: -187.5%
Return on Assets: -100.3%

Reshape Lifesciences Earnings Forecast

Key Reshape Lifesciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for RSLS is 63.93%.
  • The Selling, General & Administrative Expenses for RSLS have been equal to 205.95% of Gross Profit Margin.
  • The Research & Development expenses have been 26.68% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of RSLS is -131.22% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 12 years.

Reshape Lifesciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: RSLS
CUSIP: 761123
Website: reshapelifesciences.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.9
Quick Ratio: 0.77

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RSLS Technical Analysis vs Fundamental Analysis

Sell
34
Reshape Lifesciences (RSLS) is a Sell

Is Reshape Lifesciences a Buy or a Sell?